<DOC>
	<DOCNO>NCT00642421</DOCNO>
	<brief_summary>The purpose study assess safety profile new prolonged release formulation octreotide acetate , C2L-OCT-01 PR , administer intra muscularly every 4 , 5 6 week acromegalic patient .</brief_summary>
	<brief_title>Safety Biological Activity C2L-OCT-01 PR Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>To eligible entry study , patient must : Be great equal 18 year age . Have confirm diagnosis acromegaly base follow criterion : 1 . Typical clinical feature 2 . Mean GH concentration &gt; 1.0 ng/mL follow oral glucose tolerance test ( OGTT ) 3 . Elevated serum IGF1 level gender age match value . Fall one follow category : 1 . Has treat least last 12 week Sandostatin LAR® 10 mg 20 mg , every 28 day wellcontrolled symptom acromegaly GH concentration &lt; 2.5 ng/mL screen 2 . Be naïve prolonged release octreotide demonstrate tolerance response 7day administration Sandostatin® immediate release ( 50 µg s.c . t.i.d . ) 3 . If previously treat prolonged release octreotide , stop treatment least 12 week prior screen . If female childbearing potential , must negative pregnancy test screen use adequate mean birth control ( i.e. , oral transdermal contraceptive drug , intrauterine device , diaphragm ) study . Have ability understand requirement study , provide write informed consent participate study agree abide study restriction . Exclusion Criteria To eligible entry study , patient must NOT : If female , pregnant lactating . Have treat GH receptor antagonist ( pegvisomant ) within last 12 week . Have use dopamine agonist within last 30 day . Have undergone pituitary surgery within last 12 week . Have undergone radiotherapy within last two year . Have contraindication ( hypersensitivity octreotide formulation ) nonresponders SandostatinLAR® treatment . Be currently treat SandostatinLAR® symptom acromegaly would justify , Investigator 's opinion , dose modification . Be receive SandostatinLAR® administration every &lt; 21 &gt; 35 day . Have liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis , persistent ALT , AST &gt; 2 X ULN , serum creatinine &gt; 2 X ULN , serum bilirubin &gt; 2 X ULN . Have condition could result altered GH IGF1 level ( anorexia nervosa , Laron 's syndrome , treatment levodopa narcotic analgesic , heroin abuse . ) Have type I diabetes ( insulindependent ) uncontrolled type II diabetes ( noninsulindependent ) indicate presence ketoacidosis HbA1C great equal 10 % . Have clinically significant sign symptom potentially related tumor compression optical chiasm , base judgment investigator . Have symptomatic cholelithiasis . Have receive investigational drug participate clinical trial within last 30 day . Have clinically serious and/or unstable intercurrent infection , medical illness condition uncontrolled whose control , opinion Investigator , may jeopardize participation study complication therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Acromegaly</keyword>
</DOC>